^
Association details:
| Biomarker: | HMGB1 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Regimen: | FEC (5-fluorouracil + cyclophosphamide + epirubicin) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer
Published date:
05/21/2022
Excerpt:
The current study aims to identify and validate reliable markers that can predict pathological complete response (pCR) in fluorouracil, epirubicin, and cyclophosphamide (FEC)-based neoadjuvant therapy with (NACT/RT) and without concurrent radiation (NACT)....THBS1, TNC, and DCN were significantly overexpressed in no-pCR in both the groups. In NACT, CPA3 was significantly upregulated in the no-pCR. In NACT/RT, HnRNPAB was significantly upregulated and HMGB1 significantly downregulated in the no-pCR.
DOI:
10.1007/s10549-022-06617-0
